Payment overview · 2025
General Payments
$2,092.13
96 reported records · 24 companies
Healthcare provider profile · identity verified
Sunil Kumar Reddy Thummala, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · PARIS, TX · NPI 1740418540
Verified facts
What the public records show
CMS Open Payments records show Sunil Kumar Reddy Thummala, MD received $2,092.13 in general payments during 2025 across 96 reported records.
EMD Serono, Inc. accounted for 13.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Gamunex-C, Nuplazid, Nurtec Odt, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rytary by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Gamunex-C by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xcopri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $281.93 | 13.5% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $271.24 | 13.0% | 16 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $257.16 | 12.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $215.43 | 10.3% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $194.58 | 9.3% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.28 | 5.9% | 7 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $95.60 | 4.6% | 5 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $89.93 | 4.3% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $81.45 | 3.9% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $65.69 | 3.1% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$57.90 | 2.8% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $45.53 | 2.2% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $45.10 | 2.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.49 | 1.8% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $31.56 | 1.5% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $29.39 | 1.4% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $28.61 | 1.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.92 | 1.3% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.05 | 1.1% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $20.75 | 1.0% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $20.55 | 1.0% | 1 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.49 | 0.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.23 | 0.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.27 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,788.41 | 93 |
| Travel and Lodging | $236.91 | 1 |
| Education | $48.00 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18.81 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $254.02 | 15 | 2025 |
Source payment records
|
|||||
| VNS Therapy Normalized: vns therapy |
Device | LivaNova USA, Inc. | $236.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $220.52 | 13 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $215.43 | 11 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $194.58 | 10 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $124.28 | 7 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $81.45 | 4 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $66.52 | 4 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $65.69 | 4 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $50.72 | 3 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $48.59 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $45.10 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $41.34 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $38.49 | 2 | 2025 |
Source payment records
|
|||||
| BREKIYA Normalized: brekiya |
Drug | Amneal Pharmaceuticals LLC | $31.56 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $30.65 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $29.39 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $28.61 | 1 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $27.92 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 43 | exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
43 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 493 | 117 |
| Donepezil Hcl | Donepezil Hcl | 444 | 122 |
| Gabapentin | Gabapentin | 394 | 76 |
| Levetiracetam | Levetiracetam | 291 | 60 |
| Lamotrigine | Lamotrigine | 282 | 46 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 250 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 225 | 48 |
| Primidone | Primidone | 168 | 41 |
| Pregabalin | Pregabalin | 158 | 37 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 158 | 39 |
| Topiramate | Topiramate | 155 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 101 | 24 |
| Levothyroxine Sodium | Levothyroxine Sodium | 93 | 24 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 93 | 13 |
| Oxcarbazepine | Oxcarbazepine | 89 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 18 |
| Tramadol Hcl | Tramadol Hcl | 77 | 20 |
| Atorvastatin Calcium | Atorvastatin Calcium | 76 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 75 | 20 |
| Baclofen | Baclofen | 69 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 15 |
| Clonazepam | Clonazepam | 64 | 14 |
| Carbamazepine | Carbamazepine | 62 | 12 |
| Entacapone | Entacapone | 60 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 56 | 11 |
| Aptiom | Eslicarbazepine Acetate | 55 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 54 | 12 |
| Doxepin Hcl | Doxepin Hcl | 53 | suppressed |
| Lacosamide | Lacosamide | 52 | suppressed |
| Meloxicam | Meloxicam | 52 | 14 |
| Prednisone | Prednisone | 50 | 22 |
| Propranolol Hcl | Propranolol Hcl | 50 | 13 |
| Alprazolam | Alprazolam | 47 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 45 | 12 |
| Rytary | Carbidopa/Levodopa | 44 | suppressed |
| Botox | Onabotulinumtoxina | 43 | 20 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 43 | suppressed |
| Eliquis | Apixaban | 39 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 39 | suppressed |
| Omeprazole | Omeprazole | 38 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 37 | 14 |
| Metformin Hcl | Metformin Hcl | 36 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 35 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 32 | suppressed |
| Phenobarbital | Phenobarbital | 32 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 31 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 31 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 28 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 22 |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Losartan Potassium | Losartan Potassium | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Ingrezza | Valbenazine Tosylate | 22 | suppressed |
| Xcopri | Cenobamate | 22 | suppressed |
| Acetazolamide | Acetazolamide | 21 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 20 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Furosemide | Furosemide | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Teriflunomide | Teriflunomide | 16 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Neupro | Rotigotine | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 15 | suppressed |
| Sumatriptan | Sumatriptan | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Felbamate | Felbamate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 12 | suppressed |
| Zolmitriptan | Zolmitriptan | 12 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,092.13 · 96 records | EMD Serono, Inc. | AMYVID, AUSTEDO XR, BOTOX, BREKIYA, Briviact, GOMEKLI, Gamunex-C, General - DBS, Gocovri, KESIMPTA, KISUNLA, Leqembi, NUPLAZID, NURTEC ODT, Ocrevus Zunovo, QULIPTA, REXULTI, Rystiggo, SKYCLARYS, Symbravo, UBRELVY, UPLIZNA, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VNS Therapy, VUMERITY, VYEPTI, VYKAT XR, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error